Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

Viking Therapeutics' stock fell 12.4% in pre-market trading after pricing a $500 million offering of stock and convertible notes at a discount, upsized from $200 million. The company plans to use proceeds for drug development. The drop follows a 36% surge on positive drug data and a price target increase by Truist Securities. Broader market pressures also contributed to the decline.

Viking Therapeutics (VKTX) shares surged 36% after positive weight-loss drug data, despite a $400M share offering plan. Analysts see 109-128% upside. Retail traders speculate on potential buyouts or partnerships. Truist raised its price target to $87. VK2735 Phase 3 results expected in 2027.

Viking Therapeutics (VKTX) shares rose after Phase 2 trial results showed its obesity drug VK2735 achieved 16%-19% weight reduction. The drug demonstrated progressive weight loss and maintained results during a 12-week maintenance phase. Morgan Stanley projects the global obesity drug market could reach $150B by 2035. Viking plans Phase 3 trials with results expected in late 2027 for injectable and 2028 for oral formulations. Analysts have a consensus price target of $90.89 for VKTX.

Viking Therapeutics (VKTX) reported positive trial data for VK2735, showing significant weight loss with less frequent dosing. The stock surged 40.92% in 7 days and 56.21% in 1 year. However, its P/B ratio of 11.9x is significantly higher than peers, suggesting high expectations are already priced in. The company has no revenue and remains loss-making.

Viking Therapeutics (VKTX) plans to raise $400M via stock and convertible notes, with shares falling 8.45% post-announcement. The funds will support clinical trials for obesity and metabolic disorder treatments. The company has no revenue, a GF Score of 34, and significant insider selling.

Viking Therapeutics (VKTX) plans to raise $400M via stock and convertible notes. The company, focused on metabolic and endocrine disorders, has no revenue and relies on capital markets. Insiders have sold shares, and the GF Score™ indicates operational challenges. The offering is managed by Morgan Stanley and J.P. Morgan.